Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who werepreviously intolerant to T/S
Autore:
Yoshizawa, S; Yasuoka, A; Kikuchi, Y; Honda, M; Gatanaga, H; Tachikawa, N; Hirabayashi, Y; Oka, S;
Indirizzi:
Int Med Ctr Japan, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan Int Med Ctr Japan Tokyo Japan 1628655 Shinjuku Ku, Tokyo 1628655, Japan
Titolo Testata:
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
fascicolo: 3, volume: 85, anno: 2000,
pagine: 241 - 244
SICI:
1081-1206(200009)85:3<241:A5COOD>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
PNEUMOCYSTIS-CARINII PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE DESENSITIZATION; AEROSOLIZED PENTAMIDINE; OPPORTUNISTIC INFECTIONS; CONTROLLED TRIAL; HIV-INFECTION; TMP-SMZ; PROPHYLAXIS; AIDS; SULFONAMIDES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Oka, S Int Med Ctr Japan, AIDS Clin Ctr, Shinjuku Ku, 1-21-1 Toyama, Tokyo1628655, Japan Int Med Ctr Japan 1-21-1 Toyama Tokyo Japan 1628655 1628655, Japan
Citazione:
S. Yoshizawa et al., "A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who werepreviously intolerant to T/S", ANN ALLER A, 85(3), 2000, pp. 241-244

Abstract

Background: Trimethoprim/sulfamethoxazole (T/S) is an essential drug in patients with human immunodeficiency virus type-1 (HIV-1) infection to prevent opportunistic infections. About 40% to 60% of them develop skin rash which leads to discontinue the medication. A precise mechanism of the reaction is not known. Objective: To make the patients more tolerable to the medication and to make clear whether or not the reaction is caused by serum sulfamethoxazole-specific IgE. Methods: We established a 5-day protocol, in which T/S was administered orally as a granular form in increasing doses beginning with 0.005 g (it contains trimethoprim 0.4 mg and sulfamethoxazole 2 mg) and doubled every 12 hours until the therapeutic dose was achieved. We tried to desensitize T/S in17 patients with HIV-1 infection who were previously intolerant to T/S andmeasured the specific IgE in sera. Results: Desensitization was successfully completed in 15 (88.2%) of the patients. In two patients who failed the desensitization, one was due to fever and the other was gastric irritation. During followup in a mean period of 16.6 months (range, 8 to 23 months) as of May, 1999, none has had Pneumocystis carinii pneumonia (PCP) while receiving T/S after desensitization. Sulfamethoxazole-specific IgE did not increase, indicating that it was not the major cause of skin rash due to T/S in our cases. Conclusion: These preliminary results show that most patients who were thought to be intolerant to T/S and had no sulfamethoxazole-specific IgE can be safely desensitized and received the drug subsequently as an effective prophylaxis for PCP.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 11:31:47